What Should Life Sciences Startups Know About Reimbursement?

Reimbursement for Life Sciences Startups - JR Assocates VP Global Health Policy Jo Ellen Surzberg at Harvard Innovation Lab

Perspectives on Medical Reimbursement By JR Associates “Will my device be reimbursed?” This is one of the most important questions life sciences entrepreneurs must consider when developing new medical technology. But in today’s dynamic and complex healthcare environment, clear answers can be elusive. Harvard Innovation Lab recently invited our VP of Global Health Policy, Jo Ellen Slurzberg, to help clarify…

Read More »

How Can Medical Innovators Build a Case for Reimbursement?

Perspectives on Medical Reimbursement By JR Associates Coverage. Coding. Payment. These three factors deeply influence reimbursement for every new medical technology product. But there are no “cookie cutter” solutions. Because the reimbursement landscape is so complex and time consuming, it’s smart to start preparing for reimbursement as early as possible in the business planning and product development process. But…

Read More »

Reimbursement Strategy: Extending Product Reach Across Multiple Markets

How medical technology innovators can leverage reimbursement strategy across markets

Perspectives on Medical Reimbursement By JR Associates When medical technology companies develop reimbursement strategies for the U.S. market, it’s a smart business move to look beyond this country’s borders. That’s the advice JR Associates VP of Global Health Policy, Jo Ellen Slurzberg shared in a recent interview with Medical Device Daily. Jo Ellen acknowledged that planning…

Read More »

Bundled Payments: Implications for Medical Device & Drug/Biologic Companies

Bundled Payments for Medical Technology

Perspectives on Medical Reimbursement By JR Associates Recently, the trade press and mainstream news have been paying a lot of attention to bundled payments. Stories have focused primarily on how this shift in medical reimbursement will affect patients, providers and payers. Payers and provider networks are creating internal systems to identify the cost of treating…

Read More »

ICD-10 Impact on Cardiac Rhythm Management Procedure Coding

ICD 10 Impact on Cardiac Rhythm Management

Perspectives on Medical Reimbursement Issues By JR Associates Whitepaper: Impact of ICD-10 on Coding and Reimbursement for Cardiac Rhythm Management Procedures Authors: • Beth Bontemps, MSN, RN, NP, CCS Senior Consultant, JR Associates, Inc. • Rayellen Gilles, Customer Experience, Wolters Kluwer Law & Business Summary: By October 1, 2013, all U.S. healthcare providers are required to…

Read More »

Amyvid & Alzheimers Lesson: FDA Approval Is Not A Coverage Guarantee

Perspectives on Medical Reimbursement By JR Associates The path to advancements in disease detection and treatment is notoriously complex, circuitous and costly. However, even after FDA approval, there are no guarantees of reimbursement through CMS coverage. This is an essential lesson in the case of Eli Lilly’s Amyvid PET scan imaging agent, which is used…

Read More »

Medical Device Innovation: Is a Code Necessary for Commercial Adoption?

Perspectives on Medical Reimbursement By JR Associates For some medical devices, more than one reimbursement pathway may be viable. And, as JR Associates recently explained to Medical Device Daily, that could be the case for the Dune MarginProbe – a system that delivers real-time breast cancer detection in the operating room, by helping surgeons assess…

Read More »

Coding For Hypothermia; Clarifying New Standards

Perspectives on Medical Reimbursement By JR Associates Reprinted from The Society of Critical Care Medicine Contributing Authors: Kim Norton* Managing Partner, Argenta Advisors Seattle, Washington, USA Judy Rosenbloom** President, JR Associates Reseda, California, USA George A. Sample, MD*** Washington Hospital Center Washington, D.C. In 2005, the American Heart Association published guidelines (Class IIa and IIb)…

Read More »